NEW YORK (GenomeWeb News) - Gene therapy company Oxford Biomedica said today that it has licensed the rights for RNA interference technology from the University of Massachusetts Medical School and the Carnegie Institute of Washington.
Under the agreement, Oxford Biomedica receives non-exclusive rights under the Carnegie and UMSS licensing programs for the RNAi technology and exclusive rights for the technology’s gene therapy applications using lentiviral vectors.
Oxford Biomedica’s therapeutic vaccine and gene-based therapy programs are focused on oncology and neurotherapy.
Oxford Biomedica will provide an upfront payment, annual maintenance fees, milestone payments, and royalties on sales, the company said.
Further financial terms of the agreement were not released.